DIABETOLOGIA is a leading journal in the field of endocrinology and diabetes research, published by Springer since its inception in 1965. With an impactful presence in both Internal Medicine and Endocrinology, Diabetes and Metabolism, it is recognized in the Q1 quartile rankings for 2023, underscoring its significance and contribution to these disciplines. The journal holds impressive Scopus rankings, placing it in the top 5% of journals in its categories, making it an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practices in diabetes care and management. DIABETOLOGIA publishes a range of peer-reviewed articles, original research, and reviews that address the latest scientific developments, clinical practices, and therapeutic innovations, contributing to the global discourse on diabetes and its related health implications. Although it does not offer Open Access options, its rigorous selection process guarantees the quality and relevance of the content, solidifying its position as a reliable reference for contemporary research. For those looking to stay at the forefront of diabetes science, DIABETOLOGIA is a vital communique in the ever-evolving landscape of medical research.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

Journal of Clinical and Translational Endocrinology is a peer-reviewed open access journal published by Elsevier that has been serving the endocrinology community since its inception in 2014. With an ISSN of 2214-6237, this journal focuses on the critical intersection of clinical and translational research in endocrinology, diabetes, and metabolism, offering insights that bridge laboratory discoveries with patient care. It holds a commendable position in the field, ranking Q3 for Endocrinology and Q2 for Endocrinology, Diabetes, and Metabolism, reflecting its rigorous standards and relevance to contemporary research. Situated in the Netherlands, the journal’s aim is to foster knowledge dissemination and collaboration among professionals, researchers, and students alike, ensuring high visibility in a rapidly evolving field. The journal is committed to open access, allowing immediate access to research findings, thus maximizing their impact and facilitating advancements in clinical practice and research. With an H index that showcases its contribution to the field, Journal of Clinical and Translational Endocrinology is an essential resource for anyone invested in advancing endocrinological science.

Cardiovascular Diabetology is a prestigious open-access journal published by BMC, focusing on the intersecting fields of cardiology, endocrinology, diabetes, and internal medicine. Since its inception in 2002, this journal has established itself as a vital resource for researchers, clinicians, and academics dedicated to advancing knowledge in these areas. With an impressive impact factor reflected in its Q1 rankings for the year 2023 across its respective categories, including a ranking of 22nd in Cardiology and Cardiovascular Medicine and notably 15th in Internal Medicine, it positions itself at the forefront of scholarly communication. The journal encourages the dissemination and sharing of groundbreaking research, providing open access to foster engagement and collaboration among professionals globally. As it converges from 2002 to 2024, Cardiovascular Diabetology continues to be a pivotal platform for innovative studies, reviews, and critical insights that significantly impact clinical practices and medical education in the evolving landscape of cardiovascular health and diabetes management.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

JOURNAL OF DIABETES AND ITS COMPLICATIONS is a distinguished peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the knowledge and management of diabetes and its multifaceted complications. With an ISSN of 1056-8727 and E-ISSN 1873-460X, this journal has established its significance in the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine, as reflected in its Q2 and Q1 quartile rankings for 2023, and its commendable Scopus rankings. The journal, which has been converging knowledge since 1992 and continues to publish vital research until 2024, serves as a platform for researchers, professionals, and students aiming to delve deeper into the mechanisms, treatment, and implications of diabetes and its related disorders. While access is not open, the journal remains a critical resource for those invested in understanding and combating the challenges posed by diabetes, ultimately contributing to better health outcomes.

Journal of Diabetes Research, published by HINDAWI LTD, is a leading open-access journal dedicated to advancing the understanding and management of diabetes. Established in 2013, the journal has swiftly gained recognition, achieving a commendable Q2 ranking in both the categories of Endocrinology and Diabetes and Metabolism, as well as in Biochemistry, Genetics and Molecular Biology. With an impressive Scopus ranking of #42 out of 244 in its field, the journal provides a platform for cutting-edge research that addresses the multifaceted challenges posed by diabetes. Offering unrestricted access to its articles since its inception, the journal aims to foster collaboration and exchange of innovative ideas among researchers, clinicians, and students worldwide. It is particularly vital for those engaged in diabetes research, as it publishes influential studies that impact clinical practices and enhance patient outcomes. For academics and professionals seeking to contribute to the growing body of knowledge in diabetes, the Journal of Diabetes Research serves as a valuable resource.

DIABETIC MEDICINE is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of endocrinology, specifically focusing on the pathophysiology, management, and prevention of diabetes mellitus and its complications. With an impressive impact factor reflecting its significant role in shaping clinical practice and research, DIABETIC MEDICINE holds a prominent position among its peers, categorized in the Q1 quartiles for Endocrinology, Diabetes and Metabolism, and Internal Medicine. Since its inception in 1984, the journal has provided a platform for rigorous and innovative research, fostering collaborative efforts among researchers, clinicians, and students to enhance diabetes care. The journal is esteemed for its high-ranking performance in Scopus, highlighted by its ranking of #33 in Internal Medicine and #64 in Endocrinology, Diabetes, and Metabolism. By offering insightful access to groundbreaking studies and reviews, DIABETIC MEDICINE plays a crucial role in informing policy and improving medical outcomes for individuals with diabetes, making it an essential resource for those in medical and clinical research fields.

Current Opinion in Endocrinology, Diabetes and Obesity, published by LIPPINCOTT WILLIAMS & WILKINS, offers a critical analysis of the latest advancements and trends in the fields of endocrinology, diabetes, and obesity. With an ISSN of 1752-296X and an E-ISSN of 1752-2978, this esteemed journal provides an authoritative platform for researchers, clinicians, and healthcare professionals to stay updated on emerging research and clinical practices. Renowned for its impactful contributions, the journal holds notable rankings, including Q2 in Endocrinology and Diabetes & Metabolism, as well as a commendable Q1 in Internal Medicine, reflecting its significance in the academic community. Although currently not an open access publication, articles published from 2007 to 2024 continually enrich the discourse on pressing health issues related to endocrinology and metabolic disorders. By fostering a comprehensive understanding of the complexities within these interconnected fields, it serves as an essential resource for any professional or student engaged in health science research.

Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.